BILDYOS (denosumab-nxxp)
HYPERCALCEMIA AGENTS · GLUCOCORTICOID-INDUCED OSTEOPOROSIS ·+4
ORGANON LLC
Drug class
Hypercalcemia Agents
Hypercalcemia agents are a functional therapeutic group of pharmacologic therapies indicated to reduce pathologically elevated serum calcium levels. Read more about Hypercalcemia Agents
64 drugs in this class 39 manufacturers
Drugs in Hypercalcemia Agents
BILPREVDA (denosumab-nxxp)
HYPERCALCEMIA AGENTS · HUMORAL HYPERCALCEMIA OF MALIGNANCY ·+3
ORGANON LLC
CALCITONIN-SALMON (calcitonin,salmon,synthetic)
HYPERCALCEMIA AGENTS · HYPERCALCEMIA TREATMENT ADJUNCT ·+2
SAGENT PHARMACE
OSPOMYV (denosumab-dssb)
HYPERCALCEMIA AGENTS · GLUCOCORTICOID-INDUCED OSTEOPOROSIS ·+4
CORDAVIS LIMITE
ENOBY (denosumab-qbde)
HYPERCALCEMIA AGENTS · GLUCOCORTICOID-INDUCED OSTEOPOROSIS ·+4
Hikma Pharmaceuticals USA
XTRENBO (denosumab-qbde)
HYPERCALCEMIA AGENTS · HUMORAL HYPERCALCEMIA OF MALIGNANCY ·+3
Hikma Pharmaceuticals USA
AUKELSO (denosumab-kyqq)
HYPERCALCEMIA AGENTS · HUMORAL HYPERCALCEMIA OF MALIGNANCY ·+3
BIOCON BIOLOGIC
BOSAYA (denosumab-kyqq)
HYPERCALCEMIA AGENTS · GLUCOCORTICOID-INDUCED OSTEOPOROSIS ·+4
BIOCON BIOLOGIC
JUBEREQ (denosumab-desu)
HYPERCALCEMIA AGENTS · HUMORAL HYPERCALCEMIA OF MALIGNANCY ·+3
ACCORD BIOPHARM
Filter & compare in the drug finder →
Opens the drug finder with Hypercalcemia Agents preselected. Add indication or manufacturer filters there.
Hypercalcemia agents are a functional therapeutic group of pharmacologic therapies indicated to reduce pathologically elevated serum calcium levels.
These agents primarily work by inhibiting osteoclast-mediated bone resorption, increasing renal calcium excretion, or modulating parathyroid hormone secretion via calcium-sensing receptor activation.
Key drug classes utilized for this indication include intravenous bisphosphonates, the monoclonal RANK ligand inhibitor denosumab, calcitonin, and calcimimetics.
They are predominantly employed in the clinical management of hypercalcemia of malignancy, primary and secondary hyperparathyroidism, and severe parathyroid carcinoma.
-
nih.gov
Hypercalcemia agents are a functional therapeutic group of pharmacologic therapies indicated to reduce pathologically elevated serum calcium levels These agents primarily work by inhibiting osteoclast-mediated bone resorption, increasing renal calcium excretion, or modulating parathyroid hormone secretion via calcium-sensing receptor activation Key drug classes utilized for this indication include intravenous bisphosphonates, the monoclonal RANK ligand inhibitor denosumab, calcitonin, and calcim...
-
nih.gov
Hypercalcemia agents are a functional therapeutic group of pharmacologic therapies indicated to reduce pathologically elevated serum calcium levels Key drug classes utilized for this indication include intravenous bisphosphonates, the monoclonal RANK ligand inhibitor denosumab, calcitonin, and calcimimetics They are predominantly employed in the clinical management of hypercalcemia of malignancy, primary and secondary hyperparathyroidism, and severe parathyroid carcinoma
-
fda.gov
These agents primarily work by inhibiting osteoclast-mediated bone resorption, increasing renal calcium excretion, or modulating parathyroid hormone secretion via calcium-sensing receptor activation Key drug classes utilized for this indication include intravenous bisphosphonates, the monoclonal RANK ligand inhibitor denosumab, calcitonin, and calcimimetics They are predominantly employed in the clinical management of hypercalcemia of malignancy, primary and secondary hyperparathyroidism, and se...
-
nih.gov
These agents primarily work by inhibiting osteoclast-mediated bone resorption, increasing renal calcium excretion, or modulating parathyroid hormone secretion via calcium-sensing receptor activation
-
fda.gov
They are predominantly employed in the clinical management of hypercalcemia of malignancy, primary and secondary hyperparathyroidism, and severe parathyroid carcinoma
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.